Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]

Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PhD

The multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven trial will use time to clinical progression, defined as an increase in Clinical Dementia Rating score, as the primary end point.

Phase 3 TRAILRUNNER-ALZ 3 to Test Effects of IgG1 Monoclonal Antibody Remternetug in Early Alzheimer Disease

Videos

A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]

Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHSc

Professor, department of neurology, NYU Langone Health Center, and codirector, Epilepsy Clinical Trials, NYU Langone, Comprehensive Epilepsy Center; founder/director, Epilepsy Study Consortium.

The professor of neurology at NYU Grossman School of Medicine discussed the results of a phase 2b study on XEN1101, an investigational drug in development for focal epilepsy. [WATCH TIME: 4 minutes]

Overviewing Positive Phase 2 Data on Potassium Channel Inhibitor XEN1101: Jacqueline French, MD

Assistant professor of neurology at University of Colorado School of Medicine.

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Sana Aslam, DO, an assistant professor of neurology at University of Colorado School of Medicine. 

NeurologyLive® Clinician of the Month Spotlight: Sana Aslam, DO

Vice President of Public Policy and Advocacy, Muscular Dystrophy Association (MDA)

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.

The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP

The professor of neurology at NYU Grossman School of Medicine provided clinical insight on the uniqueness of investigational XEN1101 and the idea behind potassium channel inhibitors to treat epilepsy. [WATCH TIME: 3 minutes]

Mechanism and Promise Behind XEN1101 in Focal Epilepsy: Jacqueline French, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Slideshows

Migraine is the second leading cause of disability worldwide. New data show the number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades.

Clinical

BIO-22-NRD0187 - /clinical/headache-migraine

Neurological Disorders and the Global Burden of Disease